Reinsurance Group of America
RGA
$245.68
-0.04%
Reinsurance Group of America (RGA) is a global life and health reinsurance holding company that assumes mortality, morbidity, longevity, and financial-solutions risk from primary insurers across the U.S., Canada, Europe, Asia-Pacific, Latin America, and Africa, operating through traditional reinsurance and financial-solutions segments. As one of the largest pure-play life reinsurers in the world, RGA occupies a distinct niche between primary carriers and capital markets, competing on actuarial expertise, scale, and the ability to structure complex longevity and asset-intensive transactions rather than on commodity pricing alone. The current investor narrative centers on a powerful earnings recovery: after a soft 2024, quarterly net income has climbed from $148 million in Q4 2024 to $330 million in Q1 2026, with revenue growth accelerating to 22.4% year-over-year, and management has been deploying record operating cash flow into buybacks and dividends. The stock has responded with a 30.3% one-year gain, and the September 2026 Federal Reserve rate hike has refocused attention on RGA's spread-based, long-duration investment portfolio, which stands to benefit from a higher-for-longer rate regime even as it raises questions about credit conditions and mortality experience.…
RGA
Reinsurance Group of America
$245.68
Investment Opinion: Should I buy RGA Today?
The synthesized recommendation is Buy, anchored by the analyst consensus rating of 'buy' (recommendation mean 2.2 from nine analysts) and an average target price of $272.33, implying 10.8% upside from $245.68. The core thesis is that RGA is a deep-value reinsurer with an accelerating earnings recovery (EPS from $2.22 to $5.04 over five quarters) trading at just 8.27x forward earnings and 0.999x book, leaving room for multiple expansion as ROE climbs toward double digits.
Supporting evidence includes: (1) revenue growth of 22.39% year-over-year in Q1 2026, far above the sector median; (2) net margin expansion to 5.10% from 2.85% in Q4 2024, with gross margin reaching 28.61% in Q1 2026; (3) TTM free cash flow of $5.535 billion, funding $61 million in dividends and $94 million in buybacks while growing cash to $4.993 billion; (4) a PEG ratio of 0.176 and price-to-sales of 0.59, both far below historical ranges (PS was 1.9x-2.8x from 2021-2025); and (5) the 1.78% dividend yield with a 20.3% payout ratio, leaving substantial room for dividend growth. The forward PE of 8.27x is undemanding versus the 10-14x range typical for life reinsurers.
The biggest risks that could invalidate the thesis are: (1) a reversal in mortality experience that compresses gross margins back toward the 12-15% range, which would make the forward PE look optimistic; (2) credit deterioration in the long-duration bond portfolio under a higher-for-longer rate regime; and (3) a stall in financial-solutions transaction flow. The rating would upgrade to a stronger Buy if ROE exceeds 10% and gross margins hold above 25%, or downgrade to Hold if revenue growth decelerates below 10% or if quarterly EPS falls below $4.00. Relative to its own history (PE range 7.19x-23.63x, PB range 0.57x-2.31x) and peers, RGA appears undervalued on book and sales multiples, though the mid-range trailing PE reflects the market's skepticism about the sustainability of recent returns.
Sign up to view all
RGA 12-Month Price Forecast
RGA presents a compelling value-with-growth profile: the earnings recovery is dramatic and sustained, yet the stock trades at just 8.27x forward earnings and 0.999x book, well below historical and peer multiples. The higher-for-longer rate regime supports spread income, and the $5.5 billion TTM free cash flow provides ample capital for buybacks and dividends. However, the sustainability of the 28.61% gross margin in Q1 2026 is the key uncertainty, given the volatility of mortality experience, and the stock's proximity to its 52-week high limits margin of safety. I would upgrade to high confidence if Q2 2026 EPS exceeds $5.50 and gross margin holds above 25%, or downgrade to neutral if revenue growth decelerates below 15% or if a major adverse mortality event occurs.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Reinsurance Group of America's 12-month outlook, with a consensus price target around $272.33 and implied upside of +10.8% versus the current price.
Average Target
$272.33
0 analysts
Implied Upside
+10.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$235 - $302
Analyst target range
Nine analysts cover RGA, and the consensus is bullish: the recommendation is "buy" with a recommendation mean of 2.2 (where 1.0 is a strong buy and 3.0 is a hold), and the average target price of $272.33 implies approximately 10.8% upside from the current price of $245.68. The sentiment is reinforced by the institutional ratings history, which shows a steady stream of Overweight and Outperform reiterations from Barclays, Wells Fargo, Evercore ISI, JP Morgan, and Piper Sandler through mid-2026, with only UBS (Neutral) and Morgan Stanley (Equal Weight) sitting on the sidelines — notably, there have been no downgrades in the visible ratings history, which suggests analysts are becoming more confident rather than less. The consensus target of $272.33 sits above the 52-week high of $257.81, implying analysts expect the stock to break out to new highs, and the estimated revenue average of $31.71 billion for the coming year underpins that optimism. The target range is wide, spanning from a low of $235.00 to a high of $302.00 — a spread of $67, or roughly 27% of the current price — which signals meaningful disagreement about the durability of the earnings recovery. The low target of $235.00 (about 4.3% below the current price) prices in a scenario of margin normalization or adverse mortality experience that erodes the recent profitability gains, while the high target of $302.00 (about 22.9% above the current price) assumes continued spread expansion from the higher-rate environment, successful deployment of the $5.5 billion TTM free cash flow, and multiple expansion toward 12-13x forward earnings. The wide spread, combined with the low beta of 0.464 and the modest short interest (short ratio of 2.77 days), suggests the stock is a lower-volatility holding where the primary risk is fundamental (mortality/longevity experience and credit) rather than positioning-driven, and the absence of any sell ratings indicates that even the bears see limited downside from current levels.
Drowning in data?
Find the real signal!
Bulls vs Bears: RGA Investment Factors
The bull case currently has stronger evidence: RGA's earnings inflection is dramatic and sustained (EPS from $2.22 to $5.04 over five quarters), revenue is accelerating at 22.4%, and the stock trades at just 8.27x forward earnings with a 0.176 PEG and 0.999 price-to-book. The bear case rests on the sustainability of mortality-driven margin expansion (gross margin swung from 12.38% to 28.61% in two quarters) and the stock's proximity to its 52-week high, which limits margin of safety. The single most important tension is whether the recent gross margin expansion reflects a durable improvement in mortality experience and investment spreads or a favorable but temporary confluence of factors; if margins normalize toward the 12-15% range seen in 2024-2025, the forward PE would expand materially and the value case would weaken. Conversely, if ROE climbs toward double digits and the higher-rate regime sustains spread income, multiple expansion toward 12-13x forward earnings could drive the stock toward the $302 high target. The low beta of 0.464 and modest short interest (2.77 days) suggest the primary risk is fundamental rather than positioning-driven, making the mortality and credit outlook the key swing factor.
Bullish
- Earnings inflection is dramatic and sustained: Quarterly net income has more than doubled from $148 million in Q4 2024 to $330 million in Q1 2026, with diluted EPS rising from $2.22 to $5.04 over the same span. The progression is not a one-quarter spike: EPS climbed from $2.70 (Q2 2025) to $3.78 (Q3 2025) to $6.97 (Q4 2025) to $5.04 (Q1 2026), demonstrating a durable earnings recovery.
- Revenue growth accelerating at 22.4% YoY: Q1 2026 revenue of $6.473 billion grew 22.39% year-over-year from $5.289 billion, and the sequential path from $5.556 billion (Q2 2025) to $6.229 billion (Q3 2025) to $6.336 billion (Q4 2025) shows consistent top-line expansion. This growth rate is exceptional for a mature reinsurer and supports the shift from a value story to an earnings-compounding narrative.
- Deep value multiples with 8.3x forward PE: The stock trades at 11.34x trailing earnings and just 8.27x forward earnings, with a price-to-book of 0.999 and price-to-sales of 0.59. The PEG ratio of 0.176 is far below the 1.0 threshold, and the 1.78% dividend yield with a 20.3% payout ratio leaves ample room for continued capital returns.
- Massive free cash flow funds buybacks and dividends: TTM free cash flow of $5.535 billion dwarfs the $15.3 billion market cap, and Q1 2026 alone generated $2.873 billion versus $852 million in Q4 2025. The company returned $61 million in dividends and $94 million in buybacks while growing cash to $4.993 billion, with debt-to-equity a conservative 0.424.
Bearish
- ROE of 8.78% lags peer premium threshold: Despite the earnings recovery, ROE of 8.78% remains below the 10-12% range that typically justifies a premium multiple for life reinsurers. ROA of 0.945% is typical for a spread-based insurer, and the 5.1% net margin, while improving, is respectable rather than exceptional, suggesting the market may be right to discount the sustainability of recent returns.
- Mortality experience drives volatile gross margins: Gross margin swung from 12.38% in Q3 2025 to 28.61% in Q1 2026, and from 14.71% in Q1 2025 to 12.55% in Q4 2024, revealing extreme sensitivity to mortality and morbidity experience. A single adverse quarter could reverse the margin expansion that underpins the bull case, and the wide analyst target range of $235-$302 reflects this uncertainty.
- Stock near 52-week high limits margin of safety: At $245.68, RGA trades at 84.7% of its 52-week range ($178.21-$257.81), just 4.9% below the high. Momentum is decelerating, with the 1-month gain of 2.07% far below the 6-month gain of 24.09%, and the recent pullback from the September 3 high of $255.91 suggests profit-taking. New entries offer limited cushion if the earnings recovery stalls.
- Low beta caps upside torque without catalyst: The beta of 0.464 means RGA moves roughly 54% less than the market, which is attractive for downside protection but implies limited upside participation in broad rallies. The maximum drawdown of -13.42% is modest, but so is the torque; without a fundamental catalyst such as a major financial-solutions transaction, the stock may continue to grind rather than break out.
RGA Technical Analysis
RGA is in a sustained, well-established uptrend, with the shares up 30.27% over the past year and 20.76% year-to-date, decisively outperforming the S&P 500's 15.01% and 11.70% respective gains. At $245.68, the stock is trading at roughly 84.7% of its 52-week range (low of $178.21, high of $257.81), a positioning that reflects strong momentum but stops short of the euphoric top-of-range readings that often precede mean reversion. The 52-week high of $257.81 sits only about 4.9% above the current price, so the stock is consolidating near its highs rather than breaking out — a constructive but not yet confirmed posture that argues for patience on new entries and discipline on trailing stops. Recent momentum is positive but decelerating: the 1-month change of +2.07% and 3-month change of +16.69% are both solidly positive, yet the 1-month figure is far smaller than the 6-month gain of +24.09%, indicating the pace of advance has cooled since the spring. Notably, RGA's 1-month relative strength versus SPY is +3.03 percentage points, meaning the stock rose while the market fell 0.96% — a defensive-rotation signature consistent with the September Fed rate hike narrative favoring insurers. The 3-month relative strength of +14.69 points confirms persistent leadership, and with a short ratio of just 2.77 days, there is little bearish positioning to fuel a squeeze; the mild pullback from the September 3 high of $255.91 to $245.68 looks like orderly profit-taking rather than distribution. Key technical levels are clearly defined: support rests at the 52-week low of $178.21, with intermediate support around the $236-$240 zone that contained the August consolidation, while resistance is the 52-week high of $257.81. A breakout above $257.81 on volume would signal a fresh leg higher and likely open the door to the analyst high target of $302, whereas a breakdown below $236 would threaten the uptrend and put the $215-$220 June breakout area back in play. Volatility is remarkably low for an equity: the beta of 0.464 means RGA moves roughly 54% less than the market, and the maximum drawdown of -13.42% over the period is modest, making the stock suitable for larger position sizes but also implying that upside torque will be limited without a fundamental catalyst.
Beta
0.46
0.46x market volatility
Max Drawdown
-13.4%
Largest decline past year
52-Week Range
$178-$258
Price range past year
Annual Return
+30.3%
Cumulative gain past year
| Period | RGA Return | S&P 500 |
|---|---|---|
| 1m | +2.1% | -0.5% |
| 3m | +16.7% | +2.3% |
| 6m | +24.1% | +16.6% |
| 1y | +30.3% | +14.8% |
| ytd | +20.8% | +11.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RGA Fundamental Analysis
RGA's revenue trajectory is clearly accelerating: Q1 2026 revenue reached $6.473 billion, up 22.39% year-over-year from $5.289 billion in Q1 2025, and the sequential progression from $5.556 billion (Q2 2025) to $6.229 billion (Q3 2025) to $6.336 billion (Q4 2025) shows consistent top-line expansion rather than a one-quarter spike. The most recent quarter's gross profit of $1.852 billion on a 28.61% gross margin is a dramatic improvement from the 12.38% gross margin reported in Q3 2025 and 14.71% in Q1 2025, suggesting the financial-solutions and traditional businesses are both benefiting from favorable mortality experience and higher investment spreads. With the "Other Operating Segment" reported at $2.19 billion, the company's diversified global footprint — spanning the U.S., Europe, Asia, and Australia — provides multiple growth engines, and the 22.4% growth rate implies the investment case has shifted from a slow-growth value story to a genuine earnings-compounding narrative. Profitability has inflected sharply: Q1 2026 net income of $330 million compares to $286 million in Q1 2025 and just $148 million in Q4 2024, while the net margin expanded to 5.10% from 4.06% in Q3 2025 and 2.85% in Q4 2024. The quarterly EPS progression tells the same story — $5.04 in Q1 2026 versus $4.33 a year earlier and $2.26 in Q4 2024 — and the operating margin of 6.76% (versus a 6.81% operating income ratio in Q1 2026) reflects disciplined expense management with interest expense held steady at $99 million. For a reinsurer, a 5.1% net margin is respectable but not exceptional; the key is the direction of travel, and the 225-basis-point year-over-year margin expansion signals that underwriting and investment results are both contributing. The balance sheet is conservatively positioned: debt-to-equity of 0.424 is modest for a financial company, ROE of 8.78% is improving but still below the 10-12% range that would justify a premium multiple, and ROA of 0.945% is typical for a spread-based insurer. Cash generation is the standout — free cash flow of $2.873 billion in Q1 2026 alone, versus $852 million in Q4 2025 and $990 million in Q3 2025, with TTM free cash flow of $5.535 billion — and the company returned capital via $61 million in dividends and $94 million in buybacks while still growing cash to $4.993 billion. The current ratio of 0 and the absence of traditional working-capital metrics reflect the insurance business model, but the $5.0 billion cash position and 4.45x interest coverage (per historical ratios) indicate ample liquidity to fund growth internally without reliance on external financing.
Quarterly Revenue
$6.5B
2026-03
Revenue YoY Growth
+22.4%
YoY Comparison
Gross Margin
28.6%
Latest Quarter
Free Cash Flow
$5.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RGA Overvalued?
Because RGA is solidly profitable — Q1 2026 net income of $330 million and trailing EPS of $5.04 — the PE ratio is the appropriate primary metric, and the stock trades at 11.34x trailing earnings versus a forward PE of just 8.27x. The wide gap between trailing and forward multiples implies the market expects substantial earnings growth, consistent with the analyst consensus EPS estimate of $35.70 for the coming year (though this figure appears to be on a different share-count or operating basis than the quarterly GAAP EPS of $5.04, so it should be treated as directional). The 8.27x forward multiple is undemanding in absolute terms and suggests the market is not yet pricing in the full earnings recovery visible in the quarterly progression from $2.26 to $5.04 in diluted EPS. Relative to the broader Financial Services sector, RGA screens as a value stock: the price-to-book ratio of 0.999 means the shares trade at roughly book value, the price-to-sales ratio of 0.59 is low for a company growing revenue at 22.4%, and the PEG ratio of 0.176 is far below the 1.0 threshold that conventionally separates undervalued from overvalued growth. The dividend yield of 1.78% with a payout ratio of just 20.3% leaves substantial room for continued dividend growth and buybacks, and the EV/EBITDA of 7.69x is modest for a business generating $5.5 billion in TTM free cash flow. Compared with life insurers and reinsurers that typically trade at 1.0-1.5x book and 10-14x earnings, RGA's 1.0x book and 11.3x trailing earnings sit at the lower end of the peer range, implying the market is discounting either the sustainability of recent mortality experience or the company's below-peer ROE of 8.78%. Historically, RGA's PE has ranged from 7.19x (Q4 2025) to 23.63x (Q4 2024), with the current 11.34x sitting near the middle of that band but well below the 15-18x readings seen in 2022-2023; the price-to-book multiple of 0.999 is near the low end of its historical 0.57x-2.31x range, and the price-to-sales ratio of 0.59 is far below the 1.9x-2.8x range that prevailed from 2021 through 2025. This combination — mid-range earnings multiple, low-end book and sales multiples — suggests the market is pricing in improving but not exceptional returns, leaving room for multiple expansion if ROE continues to climb toward double digits.
PE
11.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 6x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.7x
Enterprise Value Multiple
Investment Risk Disclosure
RGA's financial risks center on the volatility of mortality and morbidity experience, which drives gross margin swings from 12.38% in Q3 2025 to 28.61% in Q1 2026 and from 14.71% in Q1 2025 to 12.55% in Q4 2024. The 5.1% net margin, while improving from 2.85% in Q4 2024, remains modest for a reinsurer and depends on favorable claims experience that can reverse quickly. Debt-to-equity of 0.424 is conservative for a financial company, but interest coverage of 4.45x and interest expense of $99 million per quarter leave limited cushion if investment spreads compress or credit losses emerge. The $5.535 billion TTM free cash flow and $4.993 billion cash position provide ample liquidity, but the business model's reliance on actuarial assumptions means a single adverse mortality quarter could erase several quarters of earnings progress.
Market and competitive risks include valuation compression if the earnings recovery stalls, given the stock trades at 84.7% of its 52-week range and just 4.9% below the high. The beta of 0.464 means RGA is less sensitive to broad market moves, but the September 2026 Fed rate hike creates a higher-for-longer regime that benefits spread income while raising credit quality concerns in the long-duration bond portfolio. Competition from larger reinsurers such as Swiss Re and Munich Re, as well as alternative capital providers, could pressure pricing in financial-solutions transactions. The wide analyst target range of $235-$302 (a $67 spread, or 27% of the current price) signals meaningful disagreement about the durability of the recovery, and the low short ratio of 2.77 days means there is little positioning-driven support if sentiment turns.
The worst-case scenario would involve a combination of adverse mortality experience, credit deterioration in the investment portfolio, and a stall in financial-solutions deal flow, causing earnings to revert toward the 2024 run-rate of $2.22-$3.03 quarterly EPS. In that scenario, the stock could retest its 52-week low of $178.21, representing a decline of approximately 27.5% from the current price of $245.68. The analyst low target of $235 implies a milder 4.3% downside, but a more severe outcome could see the stock trade toward the 2024 lows if the market reprices the earnings recovery as temporary. Given the maximum drawdown of -13.42% over the past 180 days, a 27.5% decline would be a significant outlier but is plausible if multiple adverse factors converge.
FAQ
The most severe risk is mortality and morbidity experience: gross margin swung from 12.38% in Q3 2025 to 28.61% in Q1 2026, and a reversal would undermine the earnings recovery. Second is credit risk in the long-duration investment portfolio, as the higher-for-longer rate regime could pressure credit quality and investment spreads. Third is valuation compression risk, given the stock trades at 84.7% of its 52-week range and just 4.9% below the high, leaving limited margin of safety. Fourth is competitive pressure in financial-solutions transactions from larger reinsurers and alternative capital providers, which could slow deal flow and fee income. These risks are ranked by severity, with mortality experience being the most immediate and impactful.
The 12-month forecast includes three scenarios: a base case (50% probability) targeting $255-$275, aligned with the analyst average target of $272.33; a bull case (30% probability) targeting $272-$302, driven by spread expansion and multiple re-rating; and a bear case (20% probability) targeting $178-$235, triggered by adverse mortality or credit deterioration. The base case is most likely, assuming gross margin stabilizes in the 20-25% range and revenue growth moderates to 15-18% but remains above sector averages. The key assumption is that no major adverse mortality event occurs and the Fed maintains rates at or above current levels, sustaining spread income without triggering a credit cycle.
RGA appears undervalued on multiple metrics. The forward PE of 8.27x is well below the 10-14x range typical for life reinsurers, and the price-to-book of 0.999 is at the low end of its historical 0.57x-2.31x range. The price-to-sales of 0.59 is far below the 1.9x-2.8x range that prevailed from 2021 through 2025, and the PEG of 0.176 is far below the 1.0 threshold. The trailing PE of 11.34x sits near the middle of its historical 7.19x-23.63x band, but the forward multiple implies the market expects substantial earnings growth. The valuation suggests the market is discounting the sustainability of recent mortality experience and the below-peer ROE of 8.78%, leaving room for multiple expansion if ROE climbs toward double digits.
From a risk/reward perspective, RGA offers approximately 10.8% upside to the analyst average target of $272.33 and 22.9% upside to the high target of $302, against a downside risk of 4.3% to the analyst low target of $235 and 27.5% to the 52-week low of $178.21. The stock trades at just 8.27x forward earnings and 0.999x book, with a PEG of 0.176, suggesting the market is not fully pricing the earnings recovery. However, the stock is near its 52-week high (84.7% of range), and the sustainability of the 28.61% gross margin is uncertain given mortality volatility. It is a good buy for value-oriented investors with a medium-term horizon who can tolerate the risk of a mortality-driven earnings miss, but less suitable for those seeking high-beta momentum exposure.
RGA is better suited for long-term investment than short-term trading. The beta of 0.464 means the stock moves roughly 54% less than the market, limiting short-term upside torque, while the maximum drawdown of -13.42% over the past 180 days indicates relatively low volatility. The dividend yield of 1.78% with a 20.3% payout ratio and a history of buybacks ($94 million in Q1 2026) supports a total-return approach over multiple years. Earnings visibility is moderate, with quarterly EPS ranging from $2.22 to $6.97 over the past five quarters, suggesting some volatility but an overall upward trajectory. A suggested minimum holding period is 18-24 months to allow the earnings recovery and potential multiple expansion to fully materialize.
